Detalhe da pesquisa
1.
Re-expression of epigenetically silenced PTPRR by histone acetylation sensitizes RAS-mutant lung adenocarcinoma to SHP2 inhibition.
Cell Mol Life Sci
; 81(1): 64, 2024 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38280930
2.
SHMT2 Promotes Gastric Cancer Development through Regulation of HIF1α/VEGF/STAT3 Signaling.
Int J Mol Sci
; 24(8)2023 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37108312
3.
(+)-Isocryptotanshinone derivatives and its simplified analogs as STAT3 signaling pathway inhibitors.
Bioorg Chem
; 127: 106015, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35849894
4.
Secreted HSP90α-LRP1 Signaling Promotes Tumor Metastasis and Chemoresistance in Pancreatic Cancer.
Int J Mol Sci
; 23(10)2022 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35628341
5.
Chlorogenic Acid Prevents UVA-Induced Skin Photoaging through Regulating Collagen Metabolism and Apoptosis in Human Dermal Fibroblasts.
Int J Mol Sci
; 23(13)2022 Jun 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35805942
6.
Chaperone-mediated autophagy degradation of IGF-1Rß induced by NVP-AUY922 in pancreatic cancer.
Cell Mol Life Sci
; 76(17): 3433-3447, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-30980109
7.
KLF7 promotes polyamine biosynthesis and glioma development through transcriptionally activating ASL.
Biochem Biophys Res Commun
; 514(1): 51-57, 2019 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-31018905
8.
Validating a Selective S1P1 Receptor Modulator Syl930 for Psoriasis Treatment.
Biol Pharm Bull
; 41(4): 592-596, 2018 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29415945
9.
Exploration of the Fluorescent Properties and the Modulated Activities against Sirtuin Fluorogenic Assays of Chromenone-Derived Natural Products.
Molecules
; 23(5)2018 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29724067
10.
The Characteristics of Hepatic Gsα-cAMP Axis in HSHF Diet-Fed Obese Insulin Resistance Rats and Genetic Diabetic Mice.
Biol Pharm Bull
; 40(6): 774-781, 2017 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28260721
11.
C15-methoxyphenylated 18-deoxy-herbimycin A analogues, their in vitro anticancer activity and heat shock protein 90 binding affinity.
Bioorg Med Chem Lett
; 26(17): 4287-91, 2016 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27476419
12.
Development and validation of high-throughput screening assays for poly(ADP-ribose) polymerase-2 inhibitors.
Anal Biochem
; 449: 188-94, 2014 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24382396
13.
Discovery of Natural Ah Receptor Antagonists from Salvia miltiorrhiza Bunge and Synthesis of Analogs for Tumor Immunotherapy.
J Med Chem
; 67(2): 1243-1261, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38176026
14.
Honokiol prevents lung metastasis of triple-negative breast cancer by regulating polarization and recruitment of macrophages.
Eur J Pharmacol
; 959: 176076, 2023 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37797675
15.
S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer.
Pharmaceuticals (Basel)
; 16(5)2023 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37242532
16.
Chlorogenic Acid Induced Neuroblastoma Cells Differentiation via the ACAT1-TPK1-PDH Pathway.
Pharmaceuticals (Basel)
; 16(6)2023 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37375824
17.
ACAT1 deficiency in myeloid cells promotes glioblastoma progression by enhancing the accumulation of myeloid-derived suppressor cells.
Acta Pharm Sin B
; 13(12): 4733-4747, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38045043
18.
Erratum: Author correction to "YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer" [Acta Pharmaceutica Sinica B 12 (2022) 2845-2858].
Acta Pharm Sin B
; 13(7): 3178-3179, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37521865
19.
S1PR1 serves as a viable drug target against pulmonary fibrosis by increasing the integrity of the endothelial barrier of the lung.
Acta Pharm Sin B
; 13(3): 1110-1127, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36970190
20.
YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer.
Acta Pharm Sin B
; 12(6): 2845-2858, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35755282